Format

Send to

Choose Destination
Int J Appl Basic Med Res. 2012 Jan;2(1):3-6. doi: 10.4103/2229-516X.96789.

Use of Bayesian statistics in drug development: Advantages and challenges.

Author information

1
Department of Medical Affairs and Clinical Research, Ranbaxy Laboratories Ltd., Gurgaon, Haryana, India.

Abstract

MAINLY, TWO STATISTICAL METHODOLOGIES ARE APPLICABLE TO THE DESIGN AND ANALYSIS OF CLINICAL TRIALS: frequentist and Bayesian. Most traditional clinical trial designs are based on frequentist statistics. In frequentist statistics prior information is utilized formally only in the design of a clinical trial but not in the analysis of the data. On the other hand, Bayesian statistics provide a formal mathematical method for combining prior information with current information at the design stage, during the conduct of the trial, and at the analysis stage. It is easier to implement adaptive trial designs using Bayesian methods than frequentist methods. The Bayesian approach can also be applied for post-marketing surveillance purposes and in meta-analysis. The basic tenets of good trial design are same for both Bayesian and frequentist trials. It has been recommended that the type of analysis to be used (Bayesian or frequentist) should be chosen beforehand. Switching to an analysis method that produces a more favorable outcome after observing the data is not recommended.

KEYWORDS:

Adaptive trial; Bayesian statistics; drug development

Supplemental Content

Full text links

Icon for Medknow Publications and Media Pvt Ltd Icon for PubMed Central
Loading ...
Support Center